Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a fertility drug boost miscarriage treatment success?

NCT ID NCT05940233

Disease control Sponsor: Queen Savang Vadhana Memorial Hospital, Thailand Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 17, 2026 · Last updated Aug 18, 2026 · Updated 1 time

Summary

This trial tests whether adding letrozole to the standard medication misoprostol improves the chance of completely emptying the uterus after a first-trimester pregnancy loss. About 70 women with early pregnancy loss will receive either misoprostol alone or letrozole followed by misoprostol. The study measures how often complete abortion occurs and compares side effects and time to abortion between the two groups.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
letrozole plus misoprostol
What this could lead to
If adding letrozole works better, it could offer a more effective medication option for completing early miscarriage, reducing the need for surgery.
What could go wrong
This is a small early-stage trial, and the combination may not improve complete abortion rates or could increase side effects. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

70 people

The number who actually took part.

Started

Jun 2023

Finished

May 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diafnoed Early pregnancy loss by TVS according to ACOG Practice bulletin 2018 * GA \<= 14 weeks * Os open \<= 1 cm and no conceptus per os * Hematicrit \>= 30 * Systolic blood pressure \>= 95 mmHg * Informed consent done and can follow up and comunicate in Thai language Exclusion Criteria: * Allerguc to Letrozole or Misoprostol * Intrauterine contraceptive device use * Breast feeding * Diagnoed with ectopic pregnancy or undiagnoed adnexal mass * Severe or recurrent liver disease or AST or ALT more than or equal to 3 times of upper normal limit * Multiple pregnancy * Myoma uteri that involves the endometrium ex. Submucous myoma uteri * Thromboembolism or has a history of thromboembolism * Serum creatinine \>= 2

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Medical; abortion, fetus are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Medical; abortion, fetus

Contacts and locations

Locations

  • Sutinee Srimahachota

    Bangkok, Yannawa, 10120, Thailand